2027 Precision Pediatrics: Clinical Pharmacology Mini Course

Monday, February 8, 2027, 8:00 AM - Wednesday, February 10, 2027, 12:00 PM, Kansas City, MO

The Precision Pediatrics: Clinical Pharmacology Mini Course is an introductory course covering the basics of clinical pharmacology - including pharmacokinetics, pharmacodynamics, pharmacogenetics, and adverse drug reactions. This course is open to anyone interested in learning more about precision therapeutics. As a part of this course, enrollees may choose to have their own pharmacogenetic testing performed (free of charge; limited to the first 20 participants to sign up for testing). This course is offered both in person and virtually via Teams.

For enrollees who would like to have their own pharmacogenetic testing, course registration must be completed by November 6, 2026.

• Testing requires going to a CM lab to have a cheek swab collected for DNA isolation and testing.

• Enrollees can have their cheek swabs collected at any outpatient CM lab in the Kansas City area (Adele Hall, Broadway, Northland, East, and Kansas locations) during lab hours between November 9 - December 1, 2026.

• To obtain a sufficient DNA sample, please do not eat, drink (including water), chew gum, smoke, or brush your teeth for at least 60 minutes prior to having your cheek swab collected.

• There is no charge for the testing. Samples received after December 1 will not be processed or resulted.

• If you would like to have pharmacogenetic testing and are registering after November 6th, please e-mail us to check availability of testing and to have a lab order placed for you. 

Pharmacogenetic testing is not required for the course. Enrollees who do not wish to have pharmacogenetic testing will receive a sample results report for learning purposes during the course.

Additional Course Information:

• Light refreshments will be offered in the morning.

• In the event of inclement weather, the course will be moved to virtual only using Microsoft Teams. If this occurs, enrollees will be notified in advance via e-mail.

AMA PRA Category 1 Credits™ (9.00 hours), ANCC Contact Hour(s) (9.00 hours), APRNPharm Contact Hours (9.00 hours), Non-Physician Attendance (9.00 hours)

1. Analyze patient-specific factors to determine appropriate drug selection and dosing in pediatric patients.
2. Demonstrate increased ability to evaluate pharmacokinetic and pharmacodynamic principles to predict variability in drug response and tolerability in the pediatric population

Requirements for successful completion:

• Record attendance as directed

• Engage in education and activities

• Complete the evaluation

---

Nurses

Participants who meet the requirements for successful completion will receive up to 9 contact hours, 9 of which meet the requirements for pharmacotherapeutic content.

Children’s Mercy Kansas City is approved as a provider of nursing continuing professional development by VTL Center for Professional Development an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Physicians:

Children's Mercy Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Children's Mercy Hospital  designates this Live Activity for a maximum of 9.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Cancellation Policy

In the event of inclement weather, the course will be moved to virtual only, using Microsoft Teams. If this occurs, registrants will be notified in advance by email.

Accessibility Statement
 
Children's Mercy Kansas City is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.

Mitigation of Relevant Financial Relationships

Children's Mercy Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.